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Hypogammaglobulinemia (serum IgG lower than 2 SD below the age-matched mean) and
clinical symptoms such as increased susceptibility to infection, autoimmune manifesta-
tions, granulomatous disease, and unexplained polyclonal lymphoproliferation are consid-
ered to be diagnostic hallmarks in patients with common variable immunodeficiency (CVID),
the most frequent clinically severe primary immunodeficiency syndrome. In the present
study, we investigated patients with hypogammaglobulinemia and no clinical or immuno-
logical signs of defective cell-mediated immunity and differentiated two groups on the
basis of their IgG antibody formation capacity against a variety of different antigens (bacte-
rial toxins, polysaccharide antigens, viral antigens). Patients with hypogammaglobulinemia
and intact antibody production (HIAP) displayed no or only mild susceptibility to infections,
while CVID patients showed marked susceptibility to bacterial infections that normalized
following initiation of IVIG or subcutaneous immunoglobulin replacement therapy. There
was a substantial overlap in IgG serum levels between the asymptomatic HIAP group and
the CVID patients examined before immunoglobulin treatment. HIAP patients showed nor-
mal levels of switched B-memory cells (CD19+CD27+IgD−), while both decreased and
normal levels of switched B-memory cells could be found in CVID patients. IgG antibody
response to a primary antigen, tick-borne encephalitis virus (TBEV), was defective in CVID
patients, thus confirming their substantial defect in IgG antibody production. Defective
IgG antibody production against multiple antigens could also be demonstrated in an adult
patient with recurrent infections but normal IgG levels. To facilitate early treatment before
recurrent infections may lead to organ damage, the antibody formation capacity should be
examined in hypogammaglobulinemic patients and the decision to treat should be based
on the finding of impaired IgG antibody production.
Keywords: hypogammaglobulinemia, IgG antibody deficiency, CVID, immunoglobulin treatment, IVIG, primary
vaccination
INTRODUCTION
A considerable percentage of patients seen in clinical practice,
e.g., by ENT specialists for recurrent infections (1, 2) and/or
referred for immunological evaluation have hypogammaglobu-
linemia, usually defined as a decrease in serum IgG lower than 2
SD below the age-matched mean, with a variable decrease in IgA
and/or IgM serum levels. Common variable immunodeficiency
(CVID) is the most frequent clinically severe primary immun-
odeficiency (PID) syndrome and the most common indication
for lifelong immunoglobulin replacement therapy due to pre-
dominant antibody deficiency. CVID is believed to comprise a
heterogeneous group of patients that have defective antibody for-
mation in common while other known PID syndromes should
have been excluded and substantial defects in cell-mediated immu-
nity are lacking. In view of the known heterogeneity, diagnostic
criteria for CVID are more and more under debate (3). A diagnosis
of CVID has considerable clinical relevance, as it invariably results
in long-term immunoglobulin replacement therapy, and the ques-
tion of how defective antibody formation should be demonstrated
is not uniformly clear. A serum IgG lower than 2 SD below
the age-matched mean is considered to be one diagnostic hall-
mark in patients with CVID (4, 5). Although impaired antibody
responses were included as a decisive diagnostic feature for CVID
in PID classification reports very early on [e.g., as stated in Ref.
(6):”The sine qua non-for the diagnosis of CVID is defective anti-
body formation.”], the most commonly used European Society for
Immunodeficiencies/Pan American Group for Immunodeficiency
(ESID/PAGID) definition of CVID (4) proposes hypogammaglob-
ulinemia and demonstrable impairment in antibody responses as
equivalent criteria, and it has even been reported that “positive
vaccination responses are not contradictory to the diagnosis of
CVID” (7).
In addition to hypogammaglobulinemia, the presence of clin-
ical symptoms, such as increased susceptibility to infection,
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autoimmune manifestations, granulomatous disease, unexplained
polyclonal lymphoproliferation, or an affected family member
with antibody deficiency, is mandatory for the diagnosis of CVID
in the 2014 registry diagnostic criteria for CVID proposed by
experts in the field (5), given that all other forms of primary anti-
body deficiency and secondary forms of hypogammaglobulinemia
can be excluded. Increased awareness for PID has been raised dur-
ing the last decade with the ultimate goal of an earlier diagnosis and
initiation of adequate therapy. This development is certainly desir-
able. Thus, patients with predominantly antibody deficiency such
as X-linked agammaglobulinemia (XLA) who have a long history
of clinical disease, in particular, recurrent infections of the lower
respiratory tract, are well known to be prone to developing organ
damage such as chronic lung disease, which determines their long-
term prognosis (8). However, earlier presentation of patients with
suspected PID also means that more and more patients with pre-
dominantly antibody deficiency lack a long history of clinical dis-
ease, making it necessary to initiate immunoglobulin replacement
therapy based on laboratory findings rather than patient history.
In view of this development, a more advanced laboratory defini-
tion of patients in need of intravenous immunoglobulin (IVIG) or
subcutaneous immunoglobulin (SCIG) therapy is required than
the one that is given, among others, in the currently used criteria
for CVID diagnosis (4, 5).
In the present study, we performed an immunological inves-
tigation in patients with hypogammaglobulinemia and no clini-
cal or immunological signs for defective cell-mediated immunity
and differentiated patients with CVID requiring immunoglobulin
replacement treatment from patients with hypogammaglobuline-
mia receiving no immunoglobulin therapy on the basis of their
IgG antibody formation capacity against a variety of different anti-
gens (bacterial toxins, polysaccharide antigens, viral antigens). IgG
antibody response to a primary antigen, e.g., tick-borne encephali-
tis virus (TBEV) was examined in CVID patients already receiving
IVIG therapy to reevaluate their IgG antibody production capacity.
To further underline the importance of defining clinically relevant
antibody deficiency by measuring antibody responses rather than
serum-immunoglobulin levels, a patient was presented with a mas-
sive defect in IgG antibody production comparable to that seen in
CVID despite normal IgG serum levels.
PATIENTS AND METHODS
PATIENTS WITH HYPOGAMMAGLOBULINEMIA AND CONTROLS
Forty-nine patients with hypogammaglobulinemia defined as a
serum IgG concentration below 500 mg/dl [median age (years)
37, interquartile range (IQR) 22–54, 26 men, 23 women], were
included in a retrospective observational cohort study after the
patients gave their informed consent that the anonymized data
collected as part of the routine medical attendance the patients
received could be included in a scientific publication. In these
patients, no clinical or immunological indication of defective cell-
mediated immunity (i.e., combined immunodeficiency) could be
found. The patients had been referred for immunological inves-
tigation because of hypogammaglobulinemia and/or recurrent
infections, recurrent fever of unknown origin, etc. (for a detailed
description of the clinical symptoms in the individual patients,
see Table 1) and were assigned to two groups depending on
whether they were diagnosed as CVID according to the crite-
ria established by the IUIS expert committee (6) and set on
immunoglobulin replacement therapy or left untreated. Based
on the results of the immunological workup such as determina-
tion of serum-immunoglobulin classes and IgG subclasses, IgG
antibody titers to a variety of different antigens and/or anti-
body response after booster immunization it was found out that
IgG antibody formation capacity distinguished these two groups
of hypogammaglobulinemic patients, which correlated with the
patients’ susceptibility to infections. The clinical characteriza-
tion and serum-immunoglobulin levels of the 23 hypogamma-
globulinemic patients [11 women and 12 men, median age at
diagnosis (years) 41, IQR 19.5–61.5] with intact IgG antibody
formation [hypogammaglobulinemia and intact antibody pro-
duction (HIAP)] is given in Table 1 (A). This group of patients
did not receive IVIG replacement. In 26 patients [14 men and
12 women, median age at diagnosis (years) 33, IQR 22.5–49.25,
Table 2] CVID was diagnosed according to the criteria established
by ESID (4, 5), and other PID disorders were excluded by sequence
analysis (Illumina technology performed on a MiSeq bench-top
next generation DNA sequencer) of PID genes listed in the 2011
IUIS classification (9). The CVID patients showed increased sus-
ceptibility to infections and [Table 1 (B)] and were treated with
IVIG or SCIG, and blood samples for determination of serum-
immunoglobulin levels and serum antibody concentrations were
drawn before regular IVIG or SCIG replacement therapy was
started. All results presented in this study were obtained as part of
the routine medical attendance that the patients received; no extra
venipuncture was performed on the basis of this study. Healthy
adult blood donors served as controls.
FLOW CYTOMETRY AND EXAMINATION OF HUMORAL IMMUNITY
Lymphocyte subpopulations and B cell subsets were analyzed
by flow cytometry using standard protocols with commercially
available directly conjugated monoclonal antibodies (anti-CD19
PerCP, Becton Dickinson Austria Ges.m.b.H., Schwechat, Aus-
tria; anti-IgD FITC, Becton Dickinson Austria Ges.m.b.H., anti-
CD27 PE, eBioscience, Vienna, Austria) and a FACSCalibur
(Becton Dickinson Austria Ges.m.b.H.). Data analysis was per-
formed using CellQuest software (Becton Dickinson, Austria
Ges.m.b.H.). Serum concentrations of immunoglobulins and IgG
subclasses were determined by laser nephelometry using reagents
purchased from Siemens-Behring Division (Siemens Healthcare
Diagnostics GmbH, Vienna, Austria). Serum levels of IgG and
IgM antibodies against bacterial and viral antigens were deter-
mined using commercially available enzyme-linked immunosor-
bent assay (ELISA) kits for IgG antibodies against tetanus (Vac-
cZyme Tetanus Toxoid IgG EIA, The Binding Site GmbH, Schwet-
zingen, Germany) and diphtheria toxoid (VaccZyme Diphtheria
Toxoid IgG EIA, The Binding Site GmbH), pertussis (Bordetella
pertussis IgG ELISA – VIROTECH, Sekisui Virotech GmbH, Rüs-
selsheim, Germany), TBEV TECHNOZYM® FSME (TBE) lgG
(CE), Technoclone GmbH, Vienna, Austria), mumps (Mumps-
IgG ELISA Genzyme/Virotech, Sekisui Virotech GmbH), measles
(Measles-IgG ELISA – VIROTECH, Sekisui Virotech GmbH), and
rubella virus [ETI-RUBEK-G Plus, DiaSorin S.p.A., Saluggia (VC),
Italy], VZV (VZV-IgG ELISA – VIROTECH, Sekisui Virotech
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Table 1 | (A) Clinical characteristics and serum-immunoglobulin levels in patients with hypogammaglobulinemia but intact IgG antibody
production (HIAP); (B) Clinical characteristics and serum-immunoglobulin levels in CVID patients.
Patient no. Sex Age at
diagnosis
(years)
Medical history leading to immunological evaluation Serum
immunoglobulins
(mg/dl)
IgG IgA IgM
(A)
1 M 6 Recurrent febrile episodes, hypogammaglobulinemia 360 40 95
2 M 9 Fever, diarrhea, abnormal liver function tests, hypogammaglobulinemia 291 18 26
3 M 22 Allergic rhinitis, hypogammaglobulinemia 393 64 120
4 M 25 Recurrent febrile episodes, hypogammaglobulinemia 459 115 127
5 F 37 Family history of antibody deficiency, hypogammaglobulinemia 431 162 201
6 M 34 Rec. Rhinitis, rec. gastritis, knee hurts, hypogammaglobulinemia 349 36 60
7 M 50 Nephrolithiasis, hypogammaglobulinemia 379 128 36
8 F 72 Hyperthyreosis, recurrent rhinitis 466 245 167
9 M 72 Chronic prostatitis, hypogammaglobulinemia, recurrent herpes labialis 427 530 71
10 F 89 Chronic fatigue, hypogammaglobulinemia 414 38 142
11 F 54 Chronic fatigue, hypogammaglobulinemia, recurrent sore throat, recurrent UTI 497 35 84
12 M 17 Celiac disease, herpes zoster, hypogammaglobulinemia 444 55 67
13 F 68 Chronic bronchitis, adrenal adenoma, hypogammaglobulinemia 430 139 171
14 M 8 Recurrent febrile episodes, hypogammaglobulinemia 466 112 112
15 M 14 Recurrent allergic rhinitis, recurrent herpes labialis 472 35 73
16 M 14 Recurrent rhinitis, Helicobacter gastritis, hypogammaglobulinemia 488 162 73
17 F 41 Recurrent gastritis, COPD, hypogammaglobulinemia 441 88 450
18 F 60 Polyarthralgia, hypogammaglobulinemia 437 257 234
19 F 23 Recurrent mild respiratory infections (three per year, one with antibiotic therapy) 411 93 187
20 F 69 Lichen ruber of the oral mucosa 227 89 140
21 M 53 Hypogammaglobulinemia, MGUS, DVT lower extremities with pulmonary infarction 435 54 136
22 F 51 COPD 459 38 78
23 F 63 Diabetes II, recurrent gastritis 459 91 41
Normal range (mg/dl) 815–1784 93–287 108–237
(B)
24 M 50 Gastrointestinal protein loss, malabsorption, generalized edema,
hypogammaglobulinemia, intestinal villous atrophy 3 pneumonias in the last 3 years,
recurrent bacterial bronchitis, vitiligo
<50 53 183
25 M 20 3 pneumonias in the last 3 years, recurrent bacterial bronchitis, vitiligo <50 <8 <6
26 M 27 Recurrent bacterial bronchitis ≥2 per year, recurrent folliculitis,
hypogammaglobulinemia
<50 <8 41
27 F 27 Recurrent sinusitis for 3 years, 4 pneumonias, arthralgias, rhinitis <50 <7 <7
28 M 59 One pneumonia shortly before diagnosis, recurrent sinusitis for years <50 11 29
29 F 47 Rec. bronchitis for 10 years, bronchiectasis, pansinusitis for 8 years, 3 pneumonias 56 <7 8
30 F 46 Recurrent pneumonia (≥2 per year), total 12 pneumonias 69.4 243 345
31 M 13 Recurrent pneumonia 76 <8 50
32 M 15 Recurrent pneumonia for 6 years, malabsorption, protein-loosing enteropathy 164 7 <6
33 M 39 Chronic diarrhea, herpes zoster reactivation, gastrointestinal campylobacter jejuni
infection, malabsorption
188 <7 <6
34 F 55 Recurrent pneumonia since childhood, recurrent bronchitis, otitis media, sinusitis for
5 years
199 <8 49
35 F 57 Hypogammaglobulinemia, head x-ray abnormalities suspicious of multiple myeloma 204 11 34
36 F 62 Arthritis of the hip, hypogammaglobulinemia, rec. bronchitis, rhinitis for 10 years 206 <7 51
37 F 24 Hypogammaglobulinemia, recurrent diarrhea, one pneumonia with pleuritis, genital
condyloma
210 <7 33
38 F 32 Splenectomy, recurrent bacterial bronchitis, sinusitis, hypogammaglobulinemia 217 <8 33
(Continued)
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Table 1 | Continued
Patient no. Sex Age at
diagnosis
(years)
Medical history leading to immunological evaluation Serum
immunoglobulins
(mg/dl)
IgG IgA IgM
39 M 40 Total of 13 pneumonias, recurrent bronchitis (≥5 per year) since 1978 217 <8 47
40 F 43 Hypogammaglobulinemia, recurrent bronchitis, sinusitis since childhood 219 44 26
41 F 34 Giardia lamblia enteritis, recurrent bronchitis and sinusitis for years, vitiligo 239 <8 47
42 M 29 Pneumococcal meningitis in 1976, hypogammaglobulinemia, recurrent pneumonia,
epilepsy
245 10 <7
43 M 50 Recurrent bronchitis, sinusitis for 3 years, first pneumonia 11 months ago, recurrent
diarrhea
267 11 <7
44 M 28 Recurrent pneumonia since 1978 (total of six) 327 <7 84
45 F 71 Recurrent bronchitis during the last 6 years, pulmonary obstruction 367 89 67
46 M 13 Recurrent bronchitis and diarrhea since 1995 374 <8 39
47 M 22 Recurrent diarrhea during the last 15 years, intestinal villous atrophie 379 <7 36
48 F 6 Recurrent otitis media, one pneumonia since 1996 396 242 137
49 M 13 Recurrent ITP during the last 5 years, hypogammaglobulinemia 523 12 13
Normal range (mg/dl) 815–1784 93–287 108–237
Table 2 | Patients with hypogammaglobulinemia but no susceptibility to infections show normal IgG antibody responses to a variety of
antigens.
Patient no. Serum IgG antibodies against bacterial, viral and vaccination antigens
Tet-IgG Di-IgG Hib-IgG Pn-IgG Pn-IgM TBE-IgG HBs-Ab HAV-Ab
IU/ml ug/ml Reciprocal titer VIEU/ml IU/ml IU/ml
1 1.44 (4.77) 0.45 (3.77) 2.97 42 58 3186 neg (8615)
2 4.22 1.03 1.59 (>9) 26 33 158 (417) 218 (25658) 37 (7599)
3 0.43 (5) 0.21 (>1) 1.98 <20 (101) 465 (729) na na na
4 2.38 0.23 1.5 210 214 2702 na na
5 1.52 0.28 25.01 210 314 1740 na na
6 0.97 (4.26) <0.01 0.72 (5.86) 64 102 1050 7784 8800
7 2.1 (13.71) <0.01 (1.04) 1.29 98 (536) 50 (945) 60 (1040) neg (698) neg (3832)
8 na na 1.27 (32.68) 621 180 na na na
9 0.89 0.17 >9 26 270 1375 na na
10 0.02 0.08 1.88 323 <20 na na na
11 1.04 0.06 6.31 96 72 403 (10542) neg (238) 7592
12 0.31 (23.12) 0.22 (7.37) 0.97 (2.17) 235 113 1936 448 1093
13 4.11 0.01 0.34 (>9) 119 (1429) 181 (811) 312 737 >8800
14 1.88 0.3 2.34 592 714 2683 na na
15 33 2.37 2.45 336 230 >6500 na na
16 6.2 0.04 (>15) 8.25 363 39 2701 na na
17 2.29 <0.01 0.77 277 298 1285 neg >8800
18 3.49 0.17 0.25 (1.76) 30 (242) 343 (673) 1159 13 2355
19 3.46 0.85 2.11 574 825 5289 34876 1501
20 2.08 0.01 0.17 67 (371) 148 (836) 236 356 na
21 1.28 (6.12) 0.03 (0.17) na 48 (756) 48 (2189) 26 neg 311
22 5.17 0.05 0.11 348 135 360 na na
23 0.39 (10.18) 0.03 0.39 (>9) 33 (307) 25 (200) 734 na na
Normal range >0.4 >0.4 >1 >200 >100 >310 >100 >100
Values in parentheses represent IgG antibody responses 6–8 weeks following booster immunization; na= value not available.
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GmbH), HSV-1 (anti-HSV-1 (gC1)-ELISA (IgG), Euroimmun
AG, Lübeck, Germany) and HSV-2 1 (anti-HSV-2 (gG2)-ELISA
(IgG), Euroimmun AG), hepatitis B virus (Enzygnost Anti-HBs II,
Siemens Healthcare Diagnostics GmbH), hepatitis A virus (Enzyg-
nost Anti-HAV, Siemens Healthcare Diagnostics GmbH), and
Haemophilus influenzae type b (Hib) (VaccZyme™ Hib-IgG The
Binding Site GmbH) or in-house produced ELISAs for IgG and
IgM antibodies against 23-valent pneumococcal capsular polysac-
charide and 4-valent meningococcal polysaccharide as previously
described (10).
EXAMINATION OF IgG ANTIBODY RESPONSE TO A PRIMARY ANTIGEN
IN PATIENTS WITH CVID
The major part of the CVID cohort studied has been vaccinated
against TBEV before the observation period, as it is usual practice
in Austria, and for this reason TBEV could only be applied as a
primary antigen in a subgroup of our patients. Ten patients with
CVID were vaccinated against TBEV (FSME-Immun-Inject, Bax-
ter AG,Vienna, Austria, a commercially available licensed vaccine),
a primary viral antigen for these patients. The patients were vac-
cinated twice (4-week interval between the two immunizations),
followed by a third booster vaccination 6–12 months following the
first immunization. During their participation in this vaccination
study, the 10 CVID patients received IVIG lots with a relatively low
TBEV-IgG antibody content. Serum IgG antibodies were deter-
mined by ELISA as previously described (10) before vaccination,
4–6 weeks after the second as well as before and 4 and 8 weeks after
the third vaccination. Healthy controls with a positive TBEV vac-
cination history and CVID patients receiving IVIG-replacement
therapy but no vaccination served as controls.
STATISTICAL ANALYSIS
Statistically significant differences between study groups were cal-
culated using the non-parametric two-tailed Mann–Whitney U -
test. Results are depicted using box plot diagrams, with the median
represented by a cross, the interquartile range (IQR) represented
by the box, 5- and 95-percentile values represented by the whiskers,
and minimum and maximum values represented by circles.
RESULTS
PATIENTS WITH HYPOGAMMAGLOBULINEMIA CAN BE
DIFFERENTIATED BASED ON THEIR CAPACITY TO PRODUCE IGG
ANTIBODIES
The hypogammaglobulinemic patients presented in this study
could be divided into two groups according to clinical and
immunological characteristics. First of all, most patients with
CVID showed a marked susceptibility to bacterial infections
[Table 1 (B)] that normalized following initiation of IVIG or
SCIG therapy. In contrast, patients with HIAP displayed no or
only mild susceptibility to infections, as can be seen from the clin-
ical characterization depicted in Table 1 (A), and did not require
immunoglobulin replacement therapy. HIAP patients that were
followed for many years did not show a worsening of their clinical
condition [follow-up years, median (IQR) 3.8 (0.3–9.8), n= 23].
Furthermore, the study population could be differentiated on the
basis of their IgG antibody formation capacity, which correlated
with the presence of clinical symptoms. In HIAP patients with
little or no susceptibility to infections, the intact IgG antibody
response was demonstrated by measuring serum IgG antibody
levels against a variety of different antigens (bacterial toxins, poly-
saccharide antigens, viral antigens). In addition, 14 HIAP patients
received a booster vaccination against at least one of the vaccina-
tion antigens tested and showed a normal IgG antibody response
thereafter (Table 2), while other patients in this group showed high
IgG antibodies upon first examination because of relatively recent
booster vaccinations that were performed according to current
immunization recommendations.
Serum-immunoglobulin levels were significantly lower in
CVID patients as compared to HIAP patients (Figure 1A), with
a substantial overlap of approximately 25% in serum IgG levels
between the asymptomatic HIAP group and the CVID patients
examined before immunoglobulin treatment (Figure 1A, a). In
contrast, median IgG antibody levels against pneumococcal and
Hib polysaccharides (without prior vaccination) in CVID patients
were more than one log range below the levels observed in HIAP
patients without prior vaccination (Figure 1B), with very little
overlap between the two groups: in the CVID group, only 5/26
had detectable IgG antibodies against 23-valent pneumococcal
polysaccharide (Figure 1B, a) but the median titer of the group
was significantly below that observed in healthy controls with-
out vaccination, with only a very small (5%) overlap (Figure 1B,
a). Furthermore, 95% of the CVID patients showed IgG serum
antibody levels against tetanus toxoid that were below 0.4 IU/ml
despite a positive immunization history (Figure 1B, b), while
all HIAP patients with a positive tetanus immunization history
(21/22 tested) had clearly detectable tetanus-IgG antibodies (≥0.4
IU/ml). All CVID patients tested had Hib-IgG antibodies below
1µg/ml (Figure 1B, c), antibody levels considered sufficient for
long-term protection, and 75% of the patients had no detectable
tetanus-IgG or Hib-IgG antibodies at all (Figure 1B). In the CVID
group, the IgG antibody deficiency correlated with a markedly
increased susceptibility to infections [Table 1 (B)].
B-MEMORY CELL DIFFERENTIATION IN CVID AND HIAP PATIENTS
Our findings confirm previously published evidence that the
majority of CVID patients or CVID patients as a group have
decreased switched B-memory cells, as was originally reported
by Warnatz et al. more than 10 years ago in order to identify sub-
groups of CVID patients (11), which was subsequently reevaluated
in many publications. Recently, it was reported that low numbers
of switched memory B cells correlate with infectious complica-
tions in pediatric patients with CVID (12, 13). We thus investigated
whether or not patients with hypogammaglobulinemia but intact
antibody production can be differentiated from CVID patients on
the basis of the number of switched B-memory cells in peripheral
blood. While HIAP patients showed levels of switched B-memory
cells (CD19+CD27+IgD−) that were comparable to healthy con-
trols examined in parallel, switched B-memory cells were signifi-
cantly decreased in CVID patients as a group. However, a 25–50%
overlap in switched B-memory cells could be found between CVID
patients and healthy controls (Figure 2), indicating that a consid-
erable proportion of CVID patients have switched memory B cells
within the range of healthy controls, and that low numbers of this
B cell subset can also be found in healthy individuals.
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FIGURE 1 | Serum-immunoglobulin (A) and serum-IgG antibody levels
against tetanus toxoid, haemophilus influenzae type b (Hib), and
23-valent pneumococcal polysaccharide (B) in CVID patients and
patients with hypogammaglobulinemia but intact antibody production
(HIAP). Box plot diagrams indicate the median (+), interquartile range (box),
percentiles 5 and 95 (whiskers), and minimum and maximum values (circles).
Statistical comparison between the two study groups was performed using
the Mann–Whitney U -test.
IgG ANTIBODY RESPONSE TO A PRIMARY ANTIGEN IS DEFECTIVE IN
CVID PATIENTS
IgG antibody response to a primary antigen, TBEV vaccine, was
reevaluated in 10 CVID patients receiving IVIG-replacement ther-
apy with lots containing low TBEV-IgG antibody levels. The
results depicted in Figure 3 confirm the presence of a substan-
tial defect in IgG antibody production in these patients. Only 1
of the 10 vaccinated patients showed slightly higher TBEV-IgG
antibody levels 2 months after the third vaccination as compared
to patients receiving IVIG therapy without TBEV vaccination.
In all vaccinated CVID patients, TBEV-IgG following the third
vaccination was well below the minimum levels observed in
healthy adult controls with a positive history of TBEV vaccination
(Figure 3).
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FIGURE 2 | Switched memory B cells (IgD-negative, CD27−, and
CD19-positive peripheral blood lymphocytes) were determined by
three-color flow cytometry in healthy adult controls, patients with
hypogammaglobulinemia but intact antibody production (HIAP) and
CVID patients. Box plot diagrams indicate the median (+), interquartile
range (box), percentiles 5 and 95 (whiskers), and minimum and maximum
values (circles). Statistical comparison between the study groups was
performed using the Mann–Whitney U -test.
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FIGURE 3 | IgG antibody response to a primary antigen is defective in
CVID patients. Serum IgG antibodies against tick-borne encephalitis virus
(TBEV) vaccine were determined by ELISA. Diamonds=healthy controls
with a positive TBE vaccination history (n= 16); squares=CVID patients
before TBEV vaccination (n=10); triangles=CVID patients 4–6 weeks after
second vaccination (n=10); open circles=CVID patients before third
vaccination (n=10); closed circles=CVID patients 4 weeks after third
vaccination (n=10); asterisques=CVID patients 8 weeks after third
vaccination (n=10); X= IVIG-treated CVID patients without TBEV
vaccination (n=39); crosses=TBEV-IgG antibodies in IVIG lots (diluted to
1000 mg/dl) used during vaccination study (n=10); dotted line=detection
limit for positive TBEV-IgG antibodies; median values of the respective
groups are indicated by horizontal bars.
DEFECTIVE IGG ANTIBODY PRODUCTION DESPITE NORMAL TOTAL
SERUM IGG (CASE REPORT)
A male patient, aged 39 years, was referred for immunological
evaluation because of IgA deficiency, recurrent respiratory tract
infections (recurrent otitis media and sinusitis, four infectious
episodes that required oral antibiotic therapy during the previ-
ous winter including his first pneumonia), lymphadenopathy of
the mediastinum and hilus (bronchoscopy revealed a histologic
picture compatible with the diagnosis of sarcoidosis). He had
received no treatment for his lung problems yet, in particular,
never any immunosuppressive therapy. Recent vaccination history
included revaccinations against TBEV, dT, and hepatitis A and B.
Immunological characterization revealed IgA deficiency associ-
ated with IgG2–IgG4 subclass deficiency and low to undetectable
IgG antibodies against 14 of 15 antigens tested (Table 3). The
only significant IgG antibodies found were against rubella virus
as a result of previous infection, presumably during childhood.
Total serum IgG levels were normal as were his serum IgM-levels.
Upon revaccination with 10 different antigens (including vacci-
nation against poliovirus serotypes I, II, and III), IgG antibody
responses against seven of seven antigens tested were missing
(Table 3; the seven antigens tested included 23-valent pneumococ-
cal polysaccharide and 4-valent meningococcal polysaccharide).
IVIG-replacement therapy was initiated, which led to a complete
normalization of his susceptibility to infections during a 3.5-year
follow-up. B-memory cells (CD19+CD27+ switched- and IgM-
memory B cells) were absent in peripheral blood; no indication of
defective cell-mediated immunity could be found. Other PID dis-
orders were excluded by sequence analysis (Illumina technology
performed on a MiSeq bench-top next generation DNA sequencer)
of PID genes listed in the 2011 IUIS classification (9).
DECREASE IN DELAY OF CVID DIAGNOSIS OVER THE LAST DECADE
The results presented above indicate that the decision to start
immunoglobulin replacement therapy should not be based on the
finding of hypogammaglobulinemia but rather on the demon-
stration of defective IgG antibody formation. A more precise
laboratory definition as a rationale to start immunoglobulin
replacement therapy is particularly needed in early diagnosed PID
patients before a massive history of infectious episodes and/or
infectious complications such as bronchiectases have developed.
As a result of ongoing campaigns to raise awareness for PID
more and more patients with PID are diagnosed with a relatively
short or, optimally, no history of clinical symptoms, in particu-
lar recurrent infectious episodes. We thus examined whether or
not the time between the onset of first symptoms and the date
of diagnosis of CVID became shorter in the patients diagnosed
at our institution over the last 25 years. On 81 patients diag-
nosed with CVID according to the criteria established by ESID
(4, 5) between June 30th, 1981 and September 15th, 2014, infor-
mation was available to determine the time (years) between date
of onset of first symptoms and date of diagnosis (Figure 4A) as
well as the age at diagnosis (Figure 4B). The results presented in
Figure 4A show that in our CVID patients diagnosed before June
1st, 2005 (n= 42), a median of 6.4 years (IQR, 3.6–12.3) elapsed
between onset of first symptoms and diagnosis and initiation of
therapy, while during the decade following June 1st, 2005 this
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Table 3 | Defective IgG antibody formation against a variety of antigens in a patient with normal serum IgG levels and increased susceptibility
to infections.
Age Patient Normal range
At first examination After vaccination° Under IVIG
39 years 39 years 5 months 40 years 1 month
A. SERUM-IMMUNOGLOBULIN LEVELS (mg/dl)
IgG 851 737 1649 (790–1700)
IgA <6 <6 <6 (76–450)
IgM 100 89 166 (90–350)
IgG1 683 573 1160 (500–880)
IgG2 102 96 400 (150–600)
IgG3 61 51 62 (20–100)
IgG4 <5 <6 <7 (8–120)
B. SERUM ANTIBODIES AGAINST BACTERIAL AND VIRAL ANTIGENS
Tet-IgG (IU/ml) 0.14 0.19° 4.05 >0.4
Di-IgG (IU/ml) 0.08 0.05° 0.73 >0.4
pn23-antibodies (reciprocal titer)
IgG <20 <20° 525 >200
IgM <20 42° 75 >100
Hib-IgG (ug/ml) 0.19 0.24° 5.64 >1
Mumps-IgG (VE) 1.6 n.a. 11.2 >11
Measles-IgG (VE) 1.8 n.a. 43.7 >11
Rubella-IgG (IU/ml) >176.6 n.a. >182.4 >10
Pertussis-IgG (VE) 2.8 n.a. 13.8 >10
VZV-IgG (VE) 2.6 n.a. 35.9 >11
HSV-1-IgG (VE) 20.7 n.a. n.a. >20
HSV-2-IgG (VE) 2.1 n.a. n.a. >11
TBEV-IgG (U/ml) 41 27° 444 >310
HBs-Ak (mE/ml) neg° neg° 1167 >100
HAV-Ak (IU/L) neg° neg° 4049 >100
4-Men-antibodies (reciprocal titer)
IgG <20 <20° 81 >100
IgM <20 <20 <20 >50
Eight to twelve weeks after booster vaccination against hepatitis A and B, Hib, TBEV, Pn23, DiTetPertPolio and first vaccination with tetravalent meningococcal
polysaccharide vaccine.
diagnostic delay was significantly shorter [median years (IQR])
1.9 (0.6–4.5), p= 0.000002). The age at diagnosis was compara-
ble between the two groups of patients diagnosed before and after
2005 (Figure 4B), showing that age at diagnosis in CVID patients is
not a suitable parameter to determine how long clinical symptoms
existed before diagnosis.
DISCUSSION
As a result of ongoing campaigns to raise awareness for PID more
and more patients with PID are diagnosed with a relatively short or,
optimally, no history of clinical symptoms, in particular recurrent
infectious episodes. At our institution, CVID patients diagnosed
during the last decade showed a reduction in diagnostic delay by a
median of 70% as compared to patients diagnosed earlier. While
this development is certainly desirable, it also raises the prob-
lem that diagnostic criteria (4, 5) that include mandatory clinical
symptoms will not be fulfilled if the patient is treated as early in
life as possible. This is especially true in those forms of primary
immunodeficieny that lack a definitive diagnosis, e.g., through
demonstration of a mutation in the causative gene, as is the case
in the majority of patients with CVID. In the absence of clinical
symptoms, the currently used diagnostic criteria for CVID mainly
rely on the finding of hypogammaglobulinemia. The results pre-
sented in this study show that defective IgG antibody response to a
variety of antigens rather than hypogammaglobulinemia correlate
with the need for immunoglobulin replacement therapy in indi-
vidual patients to normalize a preexisting susceptibility to infec-
tions. As individual patients with severe IgG antibody deficiency
might show IgG antibodies against selected antigens with contact,
e.g., infection early in life, as many specificities as possible should
be examined. IgG antibody responses after infection, natural
exposure, or booster immunization and against T-dependent and
T-independent, viral and bacterial, protein and polysaccharide
antigens, either vaccine-induced or infection-induced, should be
tested to provide optimal diagnostic certainty when the option
of a definitive diagnosis of CVID does not exist yet. Primary IgG
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FIGURE 4 | Decrease in delay of CVID diagnosis over the last decade.
The time (years) between date of onset of first symptoms and date of
diagnosis. (A) and the age at diagnosis (B) is given for 81 patients with
CVID divided into two groups according to whether diagnosis was made
before (n= 39) or after (n=42) June 1st, 2005. Box plot diagrams indicate
the median (+), interquartile range (box), percentiles 5 and 95 (whiskers),
and minimum and maximum values (circles). Statistical comparison
between the two groups was performed using the Mann–Whitney U -test.
The 95% confidence interval for the median calculated according to McGill
et al. (14) is indicated by horizontal bars.
antibody responses should also be a diagnostic option in selected
patients with inconclusive evaluation of booster IgG responses or
to reevaluate IgG antibody production in patients already receiving
immunoglobulin replacement therapy.
In 2014, ESID proposed new diagnostic criteria for CVID
that include either defective antibody production (defined as a
poor antibody response to vaccination or absent isohemagglu-
tinis) or low switched B-memory cells as a mandatory decisive
factor (5). Our findings confirm previously published evidence
that the majority of CVID patients and/or CVID patients as a
group have decreased switched B-memory cells, as was originally
reported by Warnatz et al. more than 10 years ago in order to
identify subgroups of CVID patients (11). However, a considerable
overlap (between 25 and 50%) in switched B-memory cell distrib-
ution could be found between CVID patients and normal healthy
controls, suggesting that CVID patients can present with normal
numbers of this B cell subset and that low numbers of switched B-
memory cells can also be found in individuals with a normal IgG
antibody production capacity, thus questioning the usefulness of
this parameter as a rationale to start immunoglobulin replacement
therapy without testing IgG antibody responses. Further studies
are required to answer the question whether very low switched
B-memory cells (below the range observed in healthy controls and
well below the 70%-of-normal-cut off as proposed in the 2014
ESID registry diagnostic criteria (5) are invariably associated with
a clinically relevant defect in IgG antibody production.
To further explore the antibody formation capacity of CVID
patients, we examined the IgG antibody response to a primary
antigen. Since ongoing immunoglobulin replacement therapy
complicates the determination of IgG antibody responses after
vaccination, we choose TBEV vaccine, an antigen suitable for pri-
mary immunization in individuals not previously vaccinated, as
IgG antibody titers are frequently low in IVIG products due to the
use of a large share of plasma from the US, where in contrast to
middle Europe, TBEV immunization is not frequently employed
(15). Previous studies proposed the use of TBEV vaccine to study
antibody response to booster vaccination in patients receiving
immunoglobulin replacement therapy (16), but primary TBEV
antibody response has not been studied in IVIG-treated CVID
patients so far. Since it is known that different IVIG lots contain
different TBEV antibody contents depending on the country of
plasma origin (15), we examined the lots of IVIG that were used
in our patients undergoing TBEV vaccination to confirm their low
TBEV antibody content. The results obtained extend our previous
knowledge of a substantial defect in antibody production in CVID
by showing a defective primary IgG antibody response in CVID
patients under IVIG therapy. These findings confirm and extend
a previous study showing defective booster antibody responses
in CVID patients under IVIG treatment on the level of defective
antibody forming cells examined by ELISPOT and plasmablasts
examined by flow cytometry of peripheral blood B cells (17).
The concept that defective IgG antibody production rather
than hypogammaglobulinemia shows the requirement for IgG
replacement is supported by findings in an adult patient with
IgA deficiency and IgG2–IgG4 deficiency who, despite his nor-
mal total IgG levels, displayed a marked defect in the formation
of IgG antibodies against both T-dependent and T-independent
antigens, associated with normalization of infectious susceptibility
under IVIG-replacement therapy. While patients with agamma-
globulinemia and complete lack of antibody production are well
known to be susceptible to infections, equivalent clinical symp-
toms can develop in patients with normal levels of total serum IgG
but defective IgG antibody production against clinically relevant
infectious organisms such as patients with selective polysaccharide
antibody deficiency (SPAD). SPAD is a well-recognized primary
predominant antibody deficiency (9) that was first described by
Umetsu et al. in patients with IgG2-subclass deficiency (18). It was
later discovered that even patients with normal IgG subclass lev-
els can fail to produce antipolysaccharide antibodies (19) and
that IVIG-replacement therapy effectively prevents infections in
these patients, despite their normal levels of total serum IgG (20).
The patient described here has IgA, IgG2, and IgG4 deficiency
in the presence of normal total serum IgG levels, but in contrast
to previously published patients with IgG subclass deficiency and
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selective anti-polysaccharide deficiency, has defective IgG antibody
response against seven of seven tested vaccination antigens, i.e.,
against T-dependent protein antigens and T-independent poly-
saccharide antigens, thus closely resembling the severe antibody
defect seen in CVID. Comparable to CVID, IVIG-replacement
therapy led to a normalization of his susceptibility to respira-
tory tract infections, and his lung abnormalities (histologically
classified as sarcoidosis) remained stable or even improved slightly.
In conclusion, the findings presented suggest that in order to
facilitate early treatment before recurrent infections may lead to
organ damage the antibody formation capacity should be exam-
ined in hypogammaglobulinemic patients and the decision to treat
should be based on the demonstration of defective IgG antibody
formation against all or the vast majority of multiple different anti-
gens tested. How many different IgG antibody specificities have to
be tested has to be determined in subsequent studies. A more
precise definition of the laboratory findings providing a rationale
to start immunoglobulin replacement in predominantly antibody
deficiency is particularly helpful in early diagnosed PID patients,
lacking a definitive genetic diagnosis and/or in patients with an
atypical clinical presentation.
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